Danaher Corporation vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 — how do they compare? Danaher Corporation trades at $207.45 (market cap $145.83B), while Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $69.36. The key difference: Danaher Corporation pays a 0.77% dividend while Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 pays none, and Danaher Corporation is trading nearer its 52-week high, Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 nearer its low. Which is the better fit depends on your goals.
| DHR | SLVO | |
|---|---|---|
Market Cap | $145.83B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $242.05 | $107.41 |
52-Week Low | $161.91 | $61.81 |
Enterprise Value | $168.04B | — |
Dividend Yield | 0.77% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
SLVO trades at $69.28, showing modest daily gains of 0.35%. Technical indicators present a mixed picture with a bullish moving average signal but bearish oscillators, including an overbought RSI. Recent news highlights volatility, with the stock crossing below its 50-day moving average last week. Fundamental data is unavailable in the provided snapshot, requiring further review of SEC filings for financial health assessment.
The outlook is cautious due to conflicting technical signals and lack of current fundamental metrics. Investment opportunity hinges on silver price trends and covered call strategy performance, but risks include commodity volatility and dollar strength impacting silver, as noted in recent financial news. Investors should seek updated financials for a complete view.
Trailing returns across standard periods
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →